Patents by Inventor Phillip A. Sharp
Phillip A. Sharp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7763446Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: GrantFiled: December 10, 2008Date of Patent: July 27, 2010Assignee: Massachusetts Institute of TechnologyInventors: Joel L. Pomerantz, Phillip A. Sharp, Carl O. Pabo
-
Publication number: 20090186843Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: July 19, 2007Publication date: July 23, 2009Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, University of Massachusetts Medical Center, Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20090100535Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: ApplicationFiled: December 10, 2008Publication date: April 16, 2009Applicant: Massachusetts Institute of TechnologyInventors: Joel L. Pomerantz, Phillip A. Sharp, Carl O. Pabo
-
Patent number: 7485441Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: GrantFiled: March 7, 2006Date of Patent: February 3, 2009Assignee: Massachusetts Institute of TechnologyInventors: Joel L. Pomerantz, Phillip A. Sharp, Carl O. Pabo
-
Publication number: 20080132461Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: July 19, 2007Publication date: June 5, 2008Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, University of Massachusetts Medical Center, Max-Planck-Gesellschaft zur Forderung derInventors: Thomas Tuschi, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Patent number: 7008780Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: GrantFiled: May 10, 2001Date of Patent: March 7, 2006Assignee: Massachusetts Institute of TechnologyInventors: Joel L. Pomerantz, Phillip A. Sharp, Carl O. Pabo
-
Publication number: 20040248296Abstract: The present invention provides siRNA methods and compositions for inhibiting HIV infection and/or replication, as well as systems for identifying effective siRNAs for inhibiting HIV and systems for studying HIV infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of an infectious agent; for example, by using siRNAs to inhibit host cell gene expression.Type: ApplicationFiled: March 20, 2003Publication date: December 9, 2004Inventors: Paul J. Beresford, Judy Lieberman, Michael F. Murray, Carl D. Novina, Phillip A. Sharp
-
Publication number: 20040214757Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transcription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: ApplicationFiled: January 4, 2002Publication date: October 28, 2004Inventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
-
Publication number: 20030126624Abstract: Chimeric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: ApplicationFiled: May 10, 2001Publication date: July 3, 2003Inventors: Joel L. Pomerantz, Phillip A. Sharp, Carl O. Pabo
-
Publication number: 20030108923Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: September 26, 2002Publication date: June 12, 2003Applicant: Whitehead Institute for Biomedical ResearchInventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Publication number: 20020086356Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.Type: ApplicationFiled: March 30, 2001Publication date: July 4, 2002Applicant: Whitehead Institute for Biomedical ResearchInventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
-
Patent number: 6410516Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: GrantFiled: June 5, 1995Date of Patent: June 25, 2002Assignees: President & Fellows of Harvard College, Massachusetts Institute of Technology, Whitehead Instittue for Biomedical ResearchInventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. Lebowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
-
Patent number: 6326166Abstract: Chineric proteins containing composite DNA-binding regions are disclosed together with DNA constructs encoding them, compositions containing them and applications in which they are useful.Type: GrantFiled: March 16, 1998Date of Patent: December 4, 2001Assignee: Massachusetts Institute of TechnologyInventors: Joel L. Pomerantz, Phillip A. Sharp, Carl O. Pabo
-
Patent number: 6150515Abstract: The invention pertains to a novel transcriptional activity factor, Tat-Stimulatory Factor, as well as genes encoding this factor and fragments and biologically functional variants thereof. The Tat-Stimulatory Factor is involved in the regulation of transcriptional elongation of HIV-1 by Tat. The invention also pertains to therapeutics involving the foregoing proteins and genes, and agents that bind to the foregoing proteins and genes.Type: GrantFiled: August 18, 1999Date of Patent: November 21, 2000Assignee: Massachusetts Institute of TechnologyInventors: Phillip A. Sharp, Qiang Zhou
-
Patent number: 6150090Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: GrantFiled: June 5, 1995Date of Patent: November 21, 2000Assignees: Massachusetts Institute of Technology, Whitehead Institute, President and Fellows of Harvard CollegeInventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
-
Patent number: 5804374Abstract: Constitutive and tissue-specific protein factors which bind to transcriptional regulatory elements of Ig genes (promoter and enhancer) are described. The factors were identified and isolated by an improved assay for protein-DNA binding. Genes encoding factors which positively regulate transcription can be isolated and employed to enhance transription of Ig genes. In particular, NF-kB, the gene encoding NF-kB, IkB and the gene encoding IkB and uses therefor.Type: GrantFiled: April 6, 1995Date of Patent: September 8, 1998Assignees: Massachusetts Insti. Technology, Whitehead Insti., Pres. and Fellow of Harvard CollegeInventors: David Baltimore, Ranjan Sen, Phillip A. Sharp, Harinder Singh, Louis Staudt, Jonathan H. LeBowitz, Albert S. Baldwin, Jr., Roger G. Clerc, Lynn M. Corcoran, Patrick A. Baeuerle, Michael J. Lenardo, Chen-Ming Fan, Thomas P. Maniatis
-
Patent number: 4687737Abstract: A method of suppressing a nonsense codon in a gene in a mammalian cell by preparing an oligonucleotide primer having a mismatched anticodon region corresponding to the nonsense codon; preparing a DNA template for production of a tRNA molecule enabling the insertion of an amino acid when the nonsense codon is translated; forming a suppressor gene from said template and primer by site specific mutagenesis; and transforming the suppressor gene into the cell.Type: GrantFiled: July 2, 1985Date of Patent: August 18, 1987Assignee: Massachusetts Institute of TechnologyInventors: Phillip A. Sharp, Mario R. Capecchi, Uttam L. RajBhandary, Frank A. Laski
-
Patent number: 4487829Abstract: Monoclonal antibodies, and a cell line characterized by its production of such monoclonal antibodies, demonstrating specific reactivity to an antigenic determinant possessed by a plurality of types of adenoviruses, a method of isolating such cell lines, and the use of such antibodies for diagnostic and therapeutic purposes as well as for identifying chemical compounds with similar properties, are disclosed.Type: GrantFiled: March 23, 1982Date of Patent: December 11, 1984Assignee: Massachusetts Institute of TechnologyInventors: Phillip A. Sharp, Constance L. Cepko, Paul Changelian